Related Experiment Video
Updated: Nov 19, 2025

06:03
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
1.6K
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose
1McMaster University, Hamilton, Ontario, Canada (Z.C.).
Annals of Internal Medicine
|February 1, 2021
Abstract
Source Citation:
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-15. 33301246.

